Patent thick­et strat­e­gy with ter­mi­nal dis­claimers helps block bi­o­log­ic com­pe­ti­tion, JA­MA let­ter shows

Bi­o­log­ics de­vel­op­ers are pro­tect­ing their most lu­cra­tive as­sets with a par­tic­u­lar type of patent that they can quick­ly pile up and dri­ve cost­ly lit­i­ga­tion around, pre­vent­ing com­pet­i­tive biosim­i­lars from com­ing to the US quick­ly, ac­cord­ing to a new JA­MA re­search let­ter.

The re­search points to so-called “ter­mi­nal dis­claimer” patents. The patents ex­pire at the same time as the orig­i­nal patent and can be ap­plied late in a bi­o­log­ic’s ex­clu­siv­i­ty pe­ri­od, but al­low man­u­fac­tur­ers to quick­ly build a fortress of patents around triv­ial changes. That “can trig­ger lengthy and cost­ly lit­i­ga­tion and add un­cer­tain­ty for biosim­i­lar man­u­fac­tur­ers who must in­val­i­date or de­sign around all patents in a bi­o­log­ic’s port­fo­lio,” said the re­searchers from the West Vir­ginia Uni­ver­si­ty Col­lege of Law, Fre­se­nius Kabi USA, and Har­vard.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER